Biogen Inc. (BIIB)
- Previous Close
204.86 - Open
204.86 - Bid 203.17 x 100
- Ask 203.39 x 100
- Day's Range
201.88 - 205.00 - 52 Week Range
189.44 - 270.50 - Volume
565,193 - Avg. Volume
1,023,409 - Market Cap (intraday)
29.613B - Beta (5Y Monthly) -0.04
- PE Ratio (TTM)
25.64 - EPS (TTM)
7.93 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
269.61
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
www.biogen.com7,570
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BIIB
View MorePerformance Overview: BIIB
Trailing total returns as of 8/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BIIB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BIIB
View MoreValuation Measures
Market Cap
29.61B
Enterprise Value
34.36B
Trailing P/E
25.64
Forward P/E
14.18
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.07
Price/Book (mrq)
1.86
Enterprise Value/Revenue
3.55
Enterprise Value/EBITDA
15.97
Financial Highlights
Profitability and Income Statement
Profit Margin
11.98%
Return on Assets (ttm)
5.19%
Return on Equity (ttm)
7.63%
Revenue (ttm)
9.67B
Net Income Avi to Common (ttm)
1.16B
Diluted EPS (ttm)
7.93
Balance Sheet and Cash Flow
Total Cash (mrq)
1.91B
Total Debt/Equity (mrq)
41.91%
Levered Free Cash Flow (ttm)
1.27B